Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia overview

Gene therapy is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia. It is administered through intravenous route. The therapeutic candidate comprises of genetically modified T-cells to express dual synthetic T cell antigen receptors (STAR-T cells). It acts by targeting cells expressing CD19 and CD22.

Bristar Immunotech Biotechnology overview

Bristar Immunotech Biotechnology (Bristar Immunotech) is a biotechnology company focused on development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T. Huaxia Yingtai is headquartered in Beijing, China.

For a complete picture of Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.